Lv1
62 积分 2023-04-21 加入
A blood-brain barrier-like vascular gate limits immunotherapy efficacy in neuroendocrine cancers
2小时前
待确认
IL-15: from discovery to FDA approval
19天前
已完结
Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy
19天前
已完结
Interleukin 2-Based Cancer Immunotherapies: The Discovery of Next-Generation Antibody-Cytokine Bispecific Antibody Drug
19天前
已完结
PD-1-targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer
19天前
已完结
Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR -Mutant Transformed Small Cell Lung Cancer
20天前
已完结
Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
20天前
已完结
Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab
20天前
已完结
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
20天前
已完结
Phase 2 Study of Amivantamab Plus Lazertinib in Previously Treated Patients With EGFR-Mutant Lung Cancers With Brain and Leptomeningeal Metastases
20天前
已完结
皖公网安备34019202002308
